Pharmaceutical Executive
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.
Following an industry's wild ride is one of the great pleasures of being a trade journalist. From that perspective, I could hardly ask for a better subject matter than pharma. Here at Pharm Exec, we've been spending a lot of time thinking about the industry and its recent past, as we prepare for our year-long celebration of our 25th anniversary. (I don't want to spoil all the surprises just yet, but we think you'll enjoy and benefit from the events and editorial projects we have in the works.) As we look over the pharma-related events that have taken place since the magazine launched in January of 1981, it's hard not to be left gasping. Here's just a tiny sample:
Patrick Clinton
I could go on and on. The point is clear, though. This has been an amazing quarter century for pharma, and it has brought us to a point at which the next quarter century can only be more of the same. New markets will emerge in India, China, and Latin America. New techniques—especially nanotechnology and gene therapy—will come of age. The industry will weather the coming years of belt tightening and become something different and, one hopes, stronger. A lot of political football will be played, and who knows, at some point, maybe some other industry will replace pharma as ball.
It should be an exciting ride, not necessarily fun, but important not just for the industry but for patients as well. I know you're on board, and your friends here at Pharm Exec are as well. We've always tried to bring you the tools and ideas you need to survive and thrive on the roller coaster that is pharma. For our next 25 years, we promise to look harder, probe deeper, think more expansively, and bring you more value. Happy birthday from us.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Recent Developments in Pharmaceutical Validation
November 1st 2024Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.